- Home
- ALXO vs GNTA Comparison
ALXO vs GNTA Comparison
Compare ALXO & GNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALXO | GNTA |
|---|---|---|
| Founded | 2015 | 2014 |
| Country | United States | Italy |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.7M | 39.4M |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ALXO | GNTA |
|---|---|---|
| Price | $1.43 | $1.89 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $3.30 | N/A |
| AVG Volume (30 Days) | ★ 330.9K | 122.5K |
| Earning Date | 11-07-2025 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.40 | $1.35 |
| 52 Week High | $2.27 | $10.00 |
Technical Indicators
Market Signals| Indicator | ALXO | GNTA |
|---|---|---|
| Relative Strength Index (RSI) | 50.21 | 40.49 |
| Support Level | $1.29 | $1.80 |
| Resistance Level | $1.56 | $2.20 |
| Average True Range (ATR) | 0.14 | 0.24 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 47.83 | 59.77 |
Price Performance
Historical ComparisonAbout ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
About GNTA Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain.